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Introduction
The research initiative “Safety Evaluation 
Ultimately Replacing Animal Testing 
(SEURAT)” (SEURAT-1 2011) was inspired 
by the considerations presented in the report 
of the U.S. National Research Council 
entitled Toxicity Testing in the 21st Century: 
A Vision and a Strategy (National Research 
Council 2007). The European Union (EU) 
policy to protect laboratory animals (EU 
2010) and the need for a new systemic 
toxicity testing arising from the complete ban 
on animal testing for cosmetic ingredients 
within the EU (2009) provided additional 
impetus for this large-scale collaborative effort. 
SEURAT-1 is a first step to addressing the 
long term strategic target and is focusing on 
the replacement of current repeated dose 
systemic toxicity testing in vivo used for 
human safety assessment. Six research projects 
and a coordination action contribute to the 
initiative, and combine the research efforts of 
over 70 European universities, public research 
institutes, and companies. SEURAT-1 is a 
public–private partnership co-financed by 
the European Commission’s FP7 Health 
Programme (EC 2007) and Cosmetics 
Europe (2015).
The SEURAT-1 strategy (Whelan 
et al. 2011) adopts a toxicological mode-
of-action (MoA) framework to describe 
how any substance may adversely affect 
human health (Ankley et al. 2010; Boobis 
et al. 2008; Krewski et al. 2010) and uses 
this knowledge to develop complementary 
theoretical, computational (in silico), and 
experimental (in vitro) models that predict 
quantitative points of departure, needed for 
safety assessment (Sturla et al. 2014). The 
research initiative aims to prove this concept 
on three levels (Whelan et al. 2012, 2013) 
by a) theoretical descriptions of adverse 
outcome pathways (AOP) based on existing 
knowledge, b) hypothesis-based testing 
strategies employing alternative in vitro and 
in silico methods with a clearly defined toxicity 
prediction goal, and c) applying existing 
information (e.g., physical chemical proper-
ties, in vivo animal data, human data) and, 
with selected data generated from alternative 
methods, achieving a regulatory-accepted 
safety assessment, based on MoA knowledge 
of the compound.
MoA describes a biological response to a 
specific chemical challenge, whereas an AOP 
is a conceptual construct describing biolog-
ical activities, beginning with a molecular 
initial event (MIE), and progressing through 
different biological levels to an observable 
adverse effect in a population (Ankley et al. 
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Background: Safety assessment for repeated dose toxicity is one of the largest challenges in the 
process to replace animal testing. This is also one of the proof of concept ambitions of SEURAT-1, 
the largest ever European Union research initiative on alternative testing, co-funded by the 
European Commission and Cosmetics Europe. This review is based on the discussion and outcome 
of a workshop organized on initiative of the SEURAT-1 consortium joined by a group of inter-
national experts with complementary knowledge to further develop traditional read-across and 
include new approach data.
oBjectives: The aim of the suggested strategy for chemical read-across is to show how a traditional 
read-across based on structural similarities between source and target substance can be strength-
ened with additional evidence from new approach data—for example, information from in vitro 
molecular screening, “-omics” assays and computational models—to reach regulatory acceptance.
Methods: We identified four read-across scenarios that cover typical human health assessment 
situations. For each such decision context, we suggested several chemical groups as examples 
to prove when read-across between group members is possible, considering both chemical and 
biological similarities.
conclusions: We agreed to carry out the complete read-across exercise for at least one chemical 
category per read-across scenario in the context of SEURAT-1, and the results of this exercise will 
be completed and presented by the end of the research initiative in December 2015.
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2010; Boobis et al. 2008). AOP constructs 
primarily related to hepatotoxicity were devel-
oped within SEURAT-1 (Landesmann and 
Vinken 2013) and included in the invento-
ries of the AOP Development Programme 
[Organisation for Economic Co-operation 
and Development (OECD) 2013a] and 
the AOP Wiki (OECD 2014b) initiatives 
of the OECD.
Predictive toxicity testing at the level 2 
proof of concept is currently about to 
be finalized by the SEURAT-1 partners 
(Berggren 2014) and will be used in the 
level 3 case studies. The consortium will carry 
out two separate case studies for applied safety 
assessment: the ab initio and the read-across 
case study. The ab initio case study will use 
results from the SEURAT-1 methods to make 
a risk assessment for repeated dose toxicity 
predicting a no-effect level of a cosmetic 
ingredient, assuming a certain exposure 
scenario. The primary goal of the read-
across case study is to increase confidence in 
read-across assessment by using data from 
alternative methods. This approach will use 
a no-effect level based on existing data for 
one substance and read it across to a similar 
substance, and the resulting safety assessment 
is expected to reach regulatory acceptable 
standards within the SEURAT-1 time frames. 
In contrast, the ab initio case study, which 
relies solely on data from alternative methods, 
is considered an initial step towards a new 
alternative risk assessment strategy. The Joint 
Research Centre, European Commission, 
organized a workshop with invited experts 
to define the read-across case study in Ispra, 
Italy, 29–30 April 2014, entitled “The 
read-across case study for safety assessment 
contributing to the SEURAT-1 proof of 
concept.” The outcome of the workshop is 
the basis for this review.
Traditional read-across is considered 
a nontesting method for filling data gaps 
which is based on an analogue or chemical 
category (van Leeuwen et al. 2009). There 
must be scientifically credible arguments to 
support the read-across, and the inherent 
uncertainties must be addressed as uncer-
tainty factors as often applied in weight-of-
evidence approaches (Cronin et al. 2013). 
The intention with the SEURAT-1 case 
study is to show how a traditional read-across 
based on structural similarities [European 
Chemicals Agency (ECHA) 2008, 2012, 
2013a, 2013b] can be strengthened with 
additional new data from in vitro testing, as 
well as complementary in silico data, when 
the structural similarities would be judged as 
insufficient to reach the necessary regulatory 
standard—for example, for registration under 
the Regulation concerning the Registration, 
Evaluation, Authorisation and Restriction 
of Chemicals (REACH) (EU 2006). The 
challenge to meet regulatory acceptance by 
increasing the confidence in the read-across 
was also described in a recently published case 
study (Ball et al. 2014).
A large proportion of higher-tier toxico-
logical studies in the REACH registration 
dossiers already apply read-across approaches. 
It was reported that 75% of all registration 
dossiers include read-across or categorization 
reasoning (ECHA 2014), and the highest 
rate of read-across was used for repeated 
dose toxicity. However, this does not mean 
that all read-across predictions satisfy the 
regulatory requirements. It rather shows 
that there is further need to improve the 
 methodology on how to perform read-across 
and categorization to achieve the standard for 
regulatory acceptance.
In the read-across context, the source 
substance is a substance with available in vivo 
data, and the target substance is a similar 
substance without sufficient data. If the 
quality of the read-across case study should be 
to meet the regulatory standard of substance 
registration under REACH, the ultimate aim 
would be to read across the full findings of a 
90-day repeated dose oral toxicity rat study 
from a source substance to a target substance, 
with a high degree of confidence in the 
predicted set of toxicological properties for 
the target substance. Within SEURAT-1, 
a conceptual framework is developed to 
combine data from in vitro methods and other 
evidence to predict the toxicological properties 
of a substance (White and Knight 2014). This 
conceptual framework can be used for the case 
study as a rational basis for supporting the 
scientific justification of read-across. Other 
frameworks were proposed using structural, 
reactivity, metabolic, and physico chemical 
similarity to evaluate the suitability of read-
across analogues (Blackburn et al. 2011; 
Wu et al. 2010), and the intention here is to 
further extend such a framework to include 
also new approach data, for example, infor-
mation from in vitro molecular screening, 
“-omics” assays and computational models.
In our case study, the read-across justifica-
tion, first, will be based on mechanistic under-
standing in combination with toxicokinetic 
and toxicodynamic assessment; second, it will 
be strengthened by selected in vitro data. An 
advantage of using data from in vitro models 
is the opportunity of using human cells or 
human-derived cell lines, with higher human 
relevance than traditional in vivo animal data. 
We therefore suggest the availability of human 
data as an additional criterion for the chemical 
selection, instead of using the animal studies 
as a gold standard. In the case study we select 
primarily liver as the target organ, because 
there is a large focus on hepatotoxicity within 
the SEURAT-1 projects; relevant AOP knowl-
edge has been gathered and many data will be 
available for well characterized liver-derived 
cells of human origin.
In this review we describe the preparatory 
step for the SEURAT-1 read-across exercise, 
setting up a strategy and identifying suitable 
scenarios and chemical categories for further 
investigation. The safety assessment based on 
this strategy will be executed within the time 
frames of SEURAT-1, and the final  evaluation 
will be reported by the end of 2015.
Methods
Read-across scenarios. Considering chemical 
similarities, we must assess different aspects 
to make the read-across scientifically justified, 
such as the chemical stability, possible forma-
tion of toxic metabolites, different active 
groups that might lead to similar or dissimilar 
behaviors, possible routes of exposure and 
concentrations at the target tissue, biotrans-
formation (before reaching, or at, the target 
organ), or observable trends. To improve and 
standardize the read-across assessment, it is 
therefore useful to identify different scenarios 
into which it would be possible to allocate 
any category of substances or substance 
analogues. This can be accomplished in 
several ways, but we agreed to include the 
toxicokinetic fate of the substance, specifi-
cally, whether adverse effect is caused by 
the activity of the compound itself at the 
target organ or by its metabolites or reaction 
products. Further, we agreed to include 
toxicodynamic behavior of the substance by 
assessing similarities in mechanism of action 
or lack of biological activity.
Four different scenarios are proposed 
to cover the most relevant read-across 
decision contexts:
I. Chemical similarity of compounds that 
do not require (or do not undergo) 
metabolism to exert a potential adverse 
human health effect
II. Chemical similarity involving chemical’s 
metabolism (resulting in exposure to the 
same/similar proximal toxicant)
III. Chemicals with generally low or no toxicity
IV. Distinguishing chemicals in a structurally 
similar category with variable toxicities 
based on MoA hypothesis.
The first decision context involves substances, 
with no metabolism or very slow metabo-
lism, that reach the target organ and are not 
converted to toxic metabolites. For in vivo 
studies it is often unknown whether the toxic 
effect is caused by the parent compound or 
the metabolite(s). However, scenario I is 
based on similarity of parent compounds and 
arguments for the exclusion of metabolites.
Read-across in the context of scenario II 
is based on the similarity of metabolites, 
The compounds in this scenario may have 
less structural similarity than compounds 
in scenario I, but can be characterized by 
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identical substructures that results in similar, 
or even identical, metabolites. Sufficient 
biological in vitro evidence might be difficult 
to find for this decision context, as many 
currently available in vitro models lack metab-
olism to the degree necessary to provide proof 
of main metabolites and detect the related 
effects. However, the HepaRG cells used 
for toxicity prediction within SEURAT-1 
(Lostia 2014; Noor and Heinzle 2014) 
have metabolic activity, and may therefore 
provide data that can be used as a basis for risk 
assessment. Evidence on any expected differ-
ences in the toxicokinetics of the source and 
target substances is a regulatory requirement 
(ECHA 2013a).
For decision context III, low or no toxicity, 
the problem is to identify on what basis to 
read-across; for example, in an absence of 
toxicity, there would be no common mecha-
nism of action between source and target 
compound. Therefore, negative read-across 
may require more information to achieve 
the same level of certainty as a positive read-
across (ECHA 2013a). Scenario III is of high 
importance from a safety assessment aspect 
because many cosmetic ingredients fit into this 
scenario, as well as substances used in other 
consumer products. Therefore read-across 
approaches that would support a conclusion 
of low toxicity are needed to empower the 
use of new less toxic substances. We agreed 
that for this scenario it would be necessary to 
strengthen the biological evidence for read-
across by using in vitro assays relevant across 
different mechanisms of action to provide a 
general profile of low or no adversities.
The decision context IV aims to estab-
lish a strong hypothesis-driven scenario based 
on mechanistic reasoning with structural 
analogues, including at least one molecule 
with markedly different potency. The chal-
lenge will then be to determine the mecha-
nistic causal relationship explaining why a 
certain analogue or analogues will lead to 
adverse outcome and others not.
The workshop participants considered 
that the four scenarios would cover all possible 
read-across situations, and each scenario will 
be further investigated by selecting well- 
characterized chemical categories.
Chemical selection. The most critical issue 
in any read-across exercise is the justifica-
tion of analogue(s) selection. To gain accep-
tance, it is essential to explain the basis for 
similarity between the target chemical and 
potential source chemicals in a robust and 
reliable manner (Cronin et al. 2013). It is also 
necessary to assess which types of uncertainties 
are related to the read-across prediction—for 
example, the number of analogues in the 
source set, the concordance with regard to the 
data, and the severity of the hazard (Blackburn 
and Stuard 2014).
Chemica l  categor ies  or  pa i r s  of 
analogues. We decided to use chemical 
categories for the case study, rather than 
using pairs of individual chemicals, because 
data available for any source substance in a 
category may be used to fill information gaps 
for substances with missing data. However, 
when making the chemical selection for the 
case study scenarios, we required that at least 
one analogue in the category must be well 
studied, with high-quality animal and human 
in vivo data, to reduce uncertainty. This crite-
rion would be met by choosing a category 
including at least one of the SEURAT-1 
gold compounds (ToxBank 2014; Wiseman 
2012). This is a set of reference compounds 
with rich database and known MoA for 
target organ systemic toxicity, selected by 
SEURAT-1 partners to test the methods 
developed within the projects. Chemicals 
can also be selected from ToxRefDB (U.S. 
EPA 2010) which includes hundreds of 
chemicals and thousands of in vivo animal 
toxicity studies, the RIFM (Research Institute 
for Fragrance Materials) Database (RIFM 
2014) or assessments made by the Scientific 
Committee on Consumer Safety (SCCS) 
(EC 2013). In addition, the SEURAT-1 
project COSMOS (COSMetics to Optimise 
Safety) (COSMOS 2011) has developed a 
database, COSMOSdb (COSMOS 2014), 
that includes a large number of toxicity 
studies with emphasis on substances used 
in cosmetics.
We agreed to choose categories for which 
toxicology studies are available for both target 
and source substances to facilitate the assess-
ment of whether additional information 
actually is strengthening the read-across case.
Chemical and biological similarity. In 
this case study a chemical category is based 
primarily on chemical similarity and then 
supported by biological arguments, but 
it could be considered to select chemicals 
based on their biological similarity, because 
of a common MoA or data profile, with less 
degree of chemical similarity. Structurally 
dissimilar chemicals can have similar toxico-
logical properties, and there might be 
reasons to start from biological similarities 
rather than being limited to the chemical 
structure thinking (Low et al. 2013), which 
is how read-across traditionally is made. A 
possibility could be to start either from the 
in vitro data profiles and then look for the 
structural similarities possibly causing the 
similar MoA. A best approach would be to 
keep an open mind and start either from 
chemical or biological similarity, and it 
should rather be a matter of fit for purpose 
based on the available information. The 
toxicity signature–driven approaches are 
still difficult due to the uncertainty in the 
relevance of the data derived from the novel 
in vitro toxicity studies. However, we suggest 
that for substances of complex, and frequently 
poorly characterized, chemical composition—
such as petrochemicals and other mixtures of 
unknown or variable composition, complex 
reaction products, or biological materials—
it is best to approach read-across from the 
perspective of a biological similarity signa-
ture. This is to avoid the inherent challenge 
of using chemical similarity as the main basis 
of read-across when there is uncertainty and 
variability in chemical composition.
It would be useful to identify closest 
neighbors both in a chemical and biological 
space for a more holistic view of the problem. 
Therefore it is necessary to progress and 
identify the biological space and further 
explore how to visualize the biological data. 
We suggest that the integrative chemical–
biological read-across (CBRA) approach 
(Low et al. 2013) for chemical hazard clas-
sification can be used to illustrate chemical 
and biological similarities between analogues. 
The U.S. EPA interactive software ToxPi 
(http://comptox.unc.edu/toxpi.php) (Reif 
et al. 2010, 2013) is also providing a tool 
to illustrate the biological data within and 
across the categories. ToxREAD (http://
www.toxgate.eu/) is a recently developed tool 
assisting in searching for similar chemicals 
considering both chemical and biological 
data from existing databases supporting a 
read-across assessment.
More efficient use of in silico tools. There 
are several potential approaches for assessing 
chemical structure similarity among target 
and source compounds. The frequently used 
Tanimoto index (Johnson and Maggiora 1990; 
Rogers and Tanimoto 1960) can be applied 
to compute similarity between structural 
fingerprints derived from one or more types 
of chemical descriptors; however, it can also 
be extended to cover mechanistic similarity 
derived from in vitro studies, because it relies 
on a comparison of two bit strings, in which 
the 1s and 0s represent the presence or absence 
of different features (e.g., absence or presence 
of a given biological effect). Additional criteria 
could be applied when defining chemical 
categories based on biologically relevant func-
tional groups and chemical moieties, as well 
as understanding of potential metabolic diver-
gence between analogues. We suggest using 
“atom centric fingerprinting” (Todeschini and 
Consonni 2009), as a molecular descriptor 
for examining structural similarity, because 
it does not rely on a pre-built (subjective) 
set of substructures. Other available in silico 
tools should also be used to better inform on 
the biological signature to supplement the 
 examination of structural similarity.
We will identify more descriptors by 
further exploiting the OECD QSAR (quanti-
tative structure–activity relationship) Toolbox 
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(OECD 2013b). For example in silico predic-
tors could be used to evaluate metabolic 
similarities to better identify the members of 
a chemical category. In the OECD QSAR 
Toolbox, usually a broad category is first 
defined (e.g., using chemical alerts for protein 
reactivity), and then the category can be 
refined adding more criteria. There is the need 
for mechanistic categorization to strengthen 
the confidence in similarity of members of 
a category, such as chemical alerts based on 
a specific mechanism, for example, DNA or 
protein binding.
A new read-across strategy. Our strategy 
is to divide the exercise in two steps. The 
first step will include building up the read-
across case based on physico-chemical and 
molecular properties, substituents, functional 
groups, and extended structural fragments, 
two-dimensional molecular similarity (i.e., 
statistical similarity based on graph theory), 
structural alert for chemical–biological interac-
tion, and AOP knowledge. Step 1 would then 
correspond to read-across without additional 
new approach data. Step 2 will add such data 
primarily from the ToxCast data from in vitro 
high throughput screening assays (Kleinstreuer 
et al. 2014; U.S. EPA 2014) and from appli-
cation of the alternative methods developed 
within the SEURAT-1 initiative. Thus, read-
across assessments will be conducted twice, 
first without any new approach data and 
then again integrating alternative data into 
the assessment and independently judging for 
robustness/confidence before and after the 
addition of the alternative data.
The in vitro data will need to be further 
complemented with toxicokinetic data for 
application in safety assessment. Further 
toxico kinetic evidence will be provided 
from the SEURAT-1 projects and is already 
available for 500–800 chemicals in ToxCast 
(Wetmore et al. 2012). The final goal is to 
evaluate whether the new approach data 
managed to strengthen the confidence in the 
read-across within a selected category. An 
added value will be to identify further in vitro 
data to be sought even if not achievable 
within the timelines of SEURAT-1.
A chemical category is chosen based on 
a clear hypothesis why the AOP would be 
possible to read-across in between source 
and target. Alternative data might be avail-
able only for certain key events, but might 
still provide confidence in that the substances 
trigger the same AOP. In addition, the 
number of analogues in a category must 
include one data rich source chemical with a 
known MoA and at least four target chemi-
cals, preferably with available data that can be 
used to build up or confirm the read-across 
arguments. We considered that categories of 
5–10 substances would be a workable size. 
At least one analogue should be hypothesized 
to be an outlier, a ringer, in the category—
that is, expected to be a target compound 
for which the read-across from the source 
compound will be clearly not acceptable. The 
inclusion of an outlier raises the confidence in 
the read-across from the source to the other 
target compounds.
Discussion
We applied the chemical selection criteria 
and agreed on chemical groups for each of 
the four read-across scenarios. To assess each 
chemical category, templates will be devel-
oped for recording and evaluating a) tradi-
tional toxicology data, b) alternative data, 
and c) robustness/confidence in read-across 
assessment (Schultz et al. 2015). For b) and 
c), common criteria are necessary to make it 
possible to compare the different read-across 
categories and understand whether the alter-
native data strengthened the confidence in 
reading across.
Scenario I: Chemical similarity of 
compounds that do not require (or do not 
undergo) metabolism to exert a potential 
adverse human health effect. Category I.I: 
Perfluoroalkyl acids (PFAAs). An example of 
a direct-acting toxicant with no metabolism 
would be perfluorooctanoic acid (PFOA). 
There are extensive animal and human in vivo 
data available on the potential “source” chem-
icals PFOA and perfluorooctane sulfonate 
(PFOS) (Nelson et al. 2010). Many alter-
natives have been synthesized and proposed 
for replacement, enabling both analogue 
and category types of read-across. The target 
compounds could be selected within the 
PFAAs that have different chain lengths. 
Chemical similarity among analogues is 
substantial and well defined. For the step 2 
assessment there is available toxico genetics 
(O’Shea et al. 2011) and ToxCast data 
(U.S. EPA 2014).
The toxicokinetics of these compounds, 
most well studied for PFOA, is very different 
between experimental animals and humans, 
and also between sexes in some species. Blood 
half-life of PFOA in humans is several years, 
whereas in all other species it varies from hours 
to weeks. The species differences in toxico-
kinetics are thought to be attributable to renal 
reabsorption (Wambaugh et al. 2013). MoA 
data are most extensive for liver effects, and 
there are more limited data on the mechanisms 
of endocrine-disruption effects. There is some 
evidence for peroxisome proliferator–activated 
receptor (PPAR) and other nuclear receptor 
(NR) activation; however, there is no evidence 
for metabolism, and it is the displacement 
of endogenous fatty acids from the transport 
proteins that may result in the disruption of 
PPAR pathways (Zhang et al. 2013).
Potential category analogues for the 
PFAAs are illustrated in Figure 1. The 
hypothesis is that they are direct-acting 
toxicants with a similar MoA. We agreed to 
investigate this category further within the 
SEURAT-1 read-across study. In vitro data 
for step 2 will be collected primarily from 
ToxCast assays (U.S. EPA 2014). In addition, 
predictive computational tools developed 
within the SEURAT-1 project COSMOS 
will be applied.
Category I.II: Phthalates. Phthalates are 
a group of chemicals that form a number 
of proximal non-electrophilic metabolites 
that are ligands for PPARα and other NRs. 
Reproductive toxicity of phthalates is the 
greatest human health concern compared 
with other end points, for example, cancer 
(Rusyn and Corton 2012). Many alterna-
tives have been synthesized and proposed as 
replacements, enabling both analogue and 
category types of read-across. Extensive 
in vivo  data are available for several 
compounds in this category (U.S. EPA 2010), 
as are human data for at least one potential 
source chemical, diethylhexyl phthalate 
(DEHP), including toxicokinetics data [U.S. 
Agency for Toxic Substances and Disease 
Registry (ATSDR) 2002]. In vitro data are 
available from ToxCast assays (U.S. EPA 
2014). However, we agreed not to include 
the phthalates in the SEURAT-1 case study 
because we considered that toxicity due to 
metabolites could not be excluded.
Category I.III: Pesticides. Several pesti-
cide groups could fit into the first scenario. 
For some chemical classes of pesticides, 
metabolism in mammalian systems does not 
yield reactive intermediates. Often many alter-
natives have been synthesized and proposed 
as replacements, enabling both analogue and 
category types of read-across. There is a large 
source of in vivo animal data resulting from 
the many regulatory studies required and 
available in ToxRefDB (U.S. EPA 2010) or 
through the European Food Safety Authority 
(EFSA 2015). MoA data are usually exten-
sive for the pesticidal property being a desired 
effect. ToxCast assay data are available for a 
vast number of pesticides (U.S. EPA 2014).
It would be necessary to further investi-
gate whether a suitable category for scenario I 
could be identified among pesticide active 
ingredients. However, this is currently 
not intended to be followed up within the 
SEURAT-1 initiative.
Scenario II: Chemical similarity involving 
metabolism (resulting in exposure to the 
same/similar toxicant). In this scenario, the 
emphasis would be on facilitating read-across 
based on toxicokinetic properties. Metabolism 
simulators from the OECD QSAR Toolbox 
(OECD 2013b) could be used. If the meta-
bolic profile looks the same between the 
source and target substances, this could be 
sufficient for reading across. In the second 
Berggren et al.
1236 volume 123 | number 12 | December 2015 • Environmental Health Perspectives
assessment step looking at in vitro data, it is 
essential to select in vitro systems with relevant 
and well-defined metabolic activity. It must be 
further evaluated to what degree the specificity 
and reactivity in metabolizing of the substance 
could be considered.
Category II.I: β-Unsaturated alcohols 
(allylic alcohols). The β-unsaturated alcohols 
undergo metabolic transformation to the 
corresponding β-unsaturated aldehyde via 
cytosolic alcohol dehydrogenase (ADH) 
(Bradbury and Christensen 1991). ADH is 
expressed in HepaRG cells, so allylic alcohols 
can be tested using methods developed and 
applied within SEURAT-1, where several 
partners are using HepaRG as a model system. 
Formation of the toxic metabolite acetalde-
hyde, which is the proximal toxicant, would 
subsequently lead to liver fibrosis through 
ROS (reactive oxygen species) formation in 
repeated dose in vivo studies (Landesmann 
et al. 2012). On the other hand, ADH is not 
expressed in HepG2 (Wilkening et al. 2003), 
which is why this cell line exposed to allylic 
alcohols can be used as negative control.
Also, data are available from ToxCast 
assays (U.S. EPA 2014) that can be used as a 
basis for the decision on further testing. The 
group with the greatest number of analogues 
in ToxCast (U.S. EPA 2014) was made by 
selecting allylic alcohols based on structural 
similarity only (e.g., using the Tanimoto 
index). However, in vitro data signatures varied 
substantially among compounds included in 
this group. This might be explained by the 
fact that all allylic alcohols are metabolized, 
but not to the same metabolite (Strubelt at 
al. 1999), which makes the group unique and 
specific. The use of cell lines that lack meta-
bolic capacity might also produce dissimilar 
ToxCast data among compounds included 
in the group. The difficulty in interpreting 
the ToxCast data demonstrated the need for 
a well-structured hypothesis in choosing the 
compounds of the category.
1-Propen-3-ol is a SEURAT-1 gold 
compound (Wiseman 2012; ToxBank 
2014) with a rich in vivo database, so it is 
suggested as a suitable source chemical in this 
category. Possible target chemicals are listed 
in Figure 2.
Our hypothesis for this read-across case 
study is that β-unsaturated alcohols are 
indirect-acting toxicants with a similar MoA, 
where metabolism via ADH leads to necrosis 
and apoptosis and subsequent liver fibrosis 
(Landesmann et al. 2012). Thus, repeated 
dose toxicity for allyl alcohol can be read-
across to the other β-unsaturated alcohols 
within the category that are metabolized to 
their corresponding α,β-unsaturated aldehyde 
via the same mechanism.
We predict a priori with high confi-
dence that compounds 1–3 in Figure 2 
elicit liver fibrosis as the source compound 
allylic alcohol. Chemical 4, 1-propanol, is 
the “ringer” chemical (a non-β-unsaturated 
alcohol) and is predicted to be an outlier 
to the category. Chemicals 5 and 6 are less 
likely to be members of the chemical category 
defined by the source compound allylic 
alcohol because the unsaturated group is not 
the terminal group in these cases. We assume 
that chemical 7, 3-methyl-1-buten-3-ol, is 
an outlier to the category because it lacks the 
ability to be metabolized to a corresponding 
β-unsaturated aldehyde via ADH.
We selected the category to be further 
investigated within the SEURAT-1 read-across 
study. In vitro data will be collected from 
No. Name CAS No. Structure
Source Perfluorooctanoic acid (PFOA) 335-67-1
1 Perfluorononanoic acid 375-95-1
2 Perfluoroheptanoic acid 375-85-9
3 Perfluorodecanoic acid 335-76-2
4 Undecafluorohexanoic acid 307-24-4
5 Perfluoroundecanoic acid 2058-94-8
6 Ammonium pentadecafluorooctanoate 3825-26-1
Figure 1. Chemicals suggested for Category I.I: Perfluoroalkyl acids (PFAAs), identified by names, CAS 
(Chemical Abstracts Service) numbers, and molecular structures. The substance indicated “source” is the 
most data-rich substance in the category with known MoA.
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SEURAT-1 assays, including the bioreactor 
models developed within the SEURAT-1 
HeMiBio project (HeMiBio 2011) to predict 
fibrosis, for the step 2 read-across exercise.
Category II.II: Halogenated solvents. 
Another candidate category to be further eval-
uated under this scenario could be the halo-
genated solvents: chlorinated and fluorinated 
solvents. Substances such as trichloroethylene 
or tetrachloroethylene are extremely data rich 
due to the rigorous risk assessments made 
in the past (EC 2004, 2005; U.S. ATSDR 
2014a, 2014b). Also, the kinetics would be 
possible to predict for these compounds. It 
was agreed that these solvents would be good 
examples because the chemical read-across 
was poor and would need strengthening argu-
ments from metabolic and mechanistic data. 
However, we agreed not to progress with 
this category within the time frame of the 
SEURAT-1 projects.
Category II.III: Pharmaceuticals, such 
as acidic drugs or acetaminophen (Tylenol®, 
Paracetamol®) with analogues. The best 
knowledge on metabolites can be found for 
pharmaceuticals. A problem for this group 
of chemicals is that many of the data are 
not publicly available, which is why the 
category was not chosen to be carried forward 
in the SEURAT-1 case study. However, it 
is recognized that acidic drugs could be of 
particular interest due to their known 
UGT-mediated activation to acyl glucuro-
nides (Davis and Hanumegowda 2009). They 
are also widely studied and, therefore, data 
rich. Acetaminophen is another example of 
an extremely data-rich substance that could 
be used as a source with a known mechanism 
through P450-mediated activation to electro-
philic substance (ToxBank 2014), which is the 
proximal toxicant.
Category II.IV: Organophosphorus 
pesticides. Pesticides are another group of 
substances where information on active metab-
olites often is available. Organophosphorous 
pesticides are an example of another P450-
mediated activating group of molecules. In 
this case, the primary toxicity is neurotoxicity 
originating from acetylcholinesterase (AChE) 
inhibition leading to increased neurotrans-
mitter activity (Fukuto 1990). This category 
will not be followed up in the read-across case 
study because liver toxicity was prioritized 
within SEURAT-1.
Scenario III: Chemicals with general 
low or no toxicity. Category III.I: Propylene 
glycol ethers. Propylene glycol ethers are 
thought to exert no or very low toxicity and 
are used in cosmetic products. There is some 
evidence in vivo for general toxic effects such 
as increased liver and kidney weight (U.S. EPA 
2010). These liver and kidney effects might 
be attributable to liver enzyme induction and 
accumulation of α2u-globulin, respectively, 
and are presumably induced by the parent 
compounds, although this has not been 
thoroughly investigated (Doi et al. 2007). In 
contrast, the ethylene glycol ethers cause both 
hematopoietic and reproductive effects (Wess 
1992). Ethylene glycol ethers are mediated 
by alkoxyacid metabolites whose forma-
tion is catalyzed by ALDH/ADH (aldehyde 
 dehydrogenase/alcohol dehydrogenase) 
(Lockley et al. 2005).
There is a considerable number of in vitro 
data from ToxCast (U.S. EPA 2014) for the 
propylene glycol ethers that confirm a general 
low toxicity profile. However, several of 
the analogues lack data, and a subset of the 
propylene glycol ethers with a more complete 
data set should be identified for the case study. 
One of the ethylene glycol ethers is suggested 
to be included in the category to better under-
stand the difference in toxicity and to assist in 
gaining confidence in readout result from the 
assumed nontoxic substances.
We suggested that this category should be 
followed-up by external collaborative partners 
to SEURAT-1. The final outcome will be 
included in the case study.
Figure 2. Chemicals suggested for Category II.I: β-unsaturated alcohols (allylic alcohols), identified by 
names, CAS numbers, and molecular structures. The substance indicated “source” is the most data-rich 
substance in the category with known MoA.
No. Name Type of alcohol CAS No. Structure
Source 1-Propen-3-ol primary allylic 107-18-6
1 1-Buten-3-ol secondary allylic 598-32-3
2 1-Penten-3-ol secondary allylic 616-25-1
3 1-Pentyn-3-ol secondary propargylics 4187-86-4
4 1-Propanol primary saturated 71-23-8
5 trans-2-Penten-1-ol primary allylic 1576-96-1
6 2-Buten-4-ol primary allylic 6117-91-5
7 3-Methyl-1-buten-3-ol tertiary allylic 115-18-4
Figure 3. Chemicals suggested for Category III.II: saturated alcohols, identified by names, CAS numbers, 
and molecular structures. The two substances indicated “source” are the most data-rich substances in 
the category with known MoA.
No. Name CAS No. Structure
1 1-Hexanol 111-27-3 OH
2 1-Heptanol 111-70-6 OH
Source 1-Octanol 111-87-5 OH
3 1-Nonanol 143-08-8 OH
4 1-Decanol 112-30-1 OH
5 1-Undecanol 112-42-5 OH
Source 1-Dodecanol 112-53-8 OH
6 1-Tridecanol 112-70-9 OH
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Category III.II: Saturated alcohols. The 
saturated alcohols are another suitable example 
chosen based on available low repeated dose 
toxicity data for some of the long-chain 
compounds. In this case, the category has 
no obvious chemical reactivity, no obvious 
bioactivity, and high no observable effect 
doses (e.g., ≥ 500 mg/kg/day) for repeated-
dose tested analogues (U.S. EPA 2010). Data 
from 28-day repeated-dose studies exist for 
several of these substances, and we suggest that 
available data can be read-across to category 
members without data. There are also ToxCast 
data (U.S. EPA 2014) for more than a dozen 
longer-chain (≥ C6) saturated alcohols. Only 
0.1–0.3% of the ToxCast assays show activity 
for these alcohols, and then only at the highest 
concentration tested. In addition, none of the 
assays with positive outcome is associated to a 
specific bioactivity.
We agreed that this category will be 
further investigated within the SEURAT-1 
case study. The hypothesis is that saturated 
alcohols of intermediate chain length (i.e., 
C6–C13) are direct-acting toxicants with a 
similar reversible MoA leading to very low 
toxicity. The chemical category (Figure 3) 
is chosen based on carbon chain length. 
Repeated dose data for the primary source 
chemicals 1-octanol and 1-dodecanol can 
be read-across to untested saturated alcohols 
of similar chain lengths. The step 2 read-
across exercise will be carried out based on 
additional in vitro evidence retrieved from 
ToxCast together with data from SEURAT-1 
in silico methods.
Scenario IV: Distinguishing chemicals in 
a structurally similar category with variable 
toxicities based on the MoA hypothesis. The 
categories chosen for this scenario include 
chemicals with moderate toxicity, to distin-
guish them from scenario III, which includes 
chemicals with low and no toxicity. However, 
more emphasis is given to the specificity 
(i.e., MoA) rather than the potency of the 
toxic effect.
Category IV.I: Short-chain carboxylic 
acids (SCCAs) .  An advantage when 
selecting the SCCAs as a category is that the 
SEURAT-1 gold compound (ToxBank 2014; 
Wiseman 2012) valproic acid (VPA) can 
be used as a source for read across to other 
carboxylic acids. VPA is a branched-chain fatty 
acid that is recognized as a substrate by the 
fatty acid oxidation pathway causing steatosis 
through mitochondrial toxicity (ToxBank 
2014). At least one of the target compounds 
selected should be a short-chained carboxylic 
acid with alkyl branching with high similarity 
to VPA. This compound is assumed to have 
the same MoA as VPA, and the observed 
effects would be similar; only the potency 
could vary. In addition the category should 
include carboxylic acids that are structurally 
less similar to VPA; for these, the variation in 
toxicity originates in different MoAs.
The category will be further investigated 
within the SEURAT-1 read-across study. 
In vitro data will be collected from several 
SEURAT-1 assays. Additional testing for the 
selected chemicals will be performed and the 
resulting data will be included in the step-2 
read-across. In addition, predictive computa-
tional models and profilers developed within 
the SEURAT-1 project COSMOS will 
contribute with additional data. Suggested 
chemicals to include in this VPA category are 
listed in Figure 4, including three negative 
targets and one positive. In addition, one 
unknown compound with an additional ester 
group was selected. This compound would be 
difficult to predict through solely the step 1 
analysis. The additional in vitro data in the 
step 2 analysis should be able to show whether 
it reacts as VPA or with an alternative MoA, 
due to, for example, ester hydrolysis.
Category IV.II: Alkyl phenols. Another 
category suggested for this scenario is the 
alkyl phenols, which includes both different 
Figure 4. Chemicals suggested for Category IV.I: short-chain carboxylic acids (SCCAs), identified by 
names, CAS numbers, and molecular structures. The substance indicated “source” is the most data-rich 
substance in the category with known MoA.
No. Name CAS No. Structure Hepatotoxic
Source Valproic acid (VPA) 99-66-1 Yes
1 2-Ethylhexanoic acid 149-57-5 Yes
2 Octanoic acid 124-07-2 No
3 Valeric acid 109-52-4 No
4 2-Methyl butyric acid 623-42-7 Unknown
5 trans-2-Pentenoic acid 13991-37-2 Yes
Table 1. Suggested read-across scenarios, corresponding chemical categories, and main adverse effects.
Read-across scenario Chemical category Main adverse effects
I. Chemical similarity of compounds that do not 
require (or do not undergo) metabolism to exert a 
potential adverse human health effect 
I.I:  Perfluoroalkyl acids (PFAAs) Hepatotoxicity, developmental toxicity
I.II:  Phthalates Reproductive toxicity, carcinogenicity
I.III:  Pesticides Dependent on category of pesticides chosen
II. Chemical similarity involving metabolism (resulting 
in exposure to the same/similar toxicant)
II.I:  β-Unsaturated alcohols (allylic alcohols) Hepatotoxicity (fibrosis), kidney and lung toxicity
II.II:  Halogenated solvents Liver and kidney toxicity
II.III: Pharmaceuticals, such as acidic drugs or acetaminophen 
(Tylenol®, Paracetamol®) with analogues
Mainly hepatotoxicity concern
II.IV: Organophosphorus pesticides Neurotoxicity
III. Chemicals with general low or no toxicity III.I:  Propylene glycol ethers Low/no toxicity
III.II:  Primary alcohols Low/no toxicity
IV. Distinguishing chemicals in a structurally similar 
category with variable toxicities based on the MoA 
hypothesis
IV.I:  Short-chain carboxylic acids (SCCAs) Hepatotoxicity (steatosis)
IV.II:  Alkyl phenols Hepatotoxicity and reproductive toxicity for 
certain members of the category
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chain lengths and different branching. This 
category contains toxic or low-toxic chemi-
cals. There are sufficient in vivo data (U.S. 
EPA 2010) available and there are also 
in vitro data from ToxCast (U.S. EPA 2014) 
for several of the chemicals in this category. 
The alkyl phenols are considered to be further 
investigated and included in the SEURAT-1 
read-across case study.
Concluding Remarks
When selecting read-across source and target 
compounds, it is necessary to address the 
following considerations:
• Type of a read-across approach (analogue 
or category)
• Characterization of the read-across scenario
• Identification of the MoA of source 
compound
• Read-across hypothesis
• Similarity between source and target 
compounds
• Whether human data are available
• Whether in vivo animal data are available
• Whether in vitro data are available
• Uncertainties associated with the read-across 
both before and after the addition of the 
novel in vitro data.
Chemical categories were identified for four 
different decision contexts chosen to cover 
realistically possible read-across situations, 
as listed in Table 1. For each scenario, one 
category was selected to be included in the 
SEURAT-1 read-across case study. Each of 
the four selected read-across categories will 
now be investigated in a two-step procedure. 
In a first step, all available information (e.g., 
human and animal in vivo data, in vitro data, 
metabolism data) will be collected, including 
additional molecular descriptors to further 
investigate chemical similarities within a 
category. Read-across assessments will be 
conducted using available in vivo test data as 
their primary basis; in a second step, novel 
in vitro and in silico data will be integrated 
and the read-across assessment repeated. It 
will be necessary to evaluate robustness/confi-
dence in the read-across assessment before 
and after the addition of the alternative data. 
It is also important to agree on how best to 
visualize results, especially from the novel 
data streams.
The aim of the exercise described herein 
is to strengthen the read-across arguments 
with in vitro and in silico profiling and 
toxicokinetics modeling for the four read-
across scenarios with illustrative examples of 
chemical groups for each decision context. 
Scenario III is especially challenging, including 
the read-across of no or low toxicity. How to 
address uncertainty when reading across no 
adversity was discussed in a recent published 
case study (Ball et al. 2014) and will be further 
considered in the present exercise.
Based on the outcomes of the workshop 
and follow-up studies, an advisory document 
will be drafted on how to apply data from 
alternative methods to support read-across 
categories, with the intention to propose 
the document as an accompaniment to the 
new OECD guidance on chemical grouping 
(OECD 2014a). The suggested SEURAT-1 
read-across methodology could also be linked 
with the more formalized approach already 
implemented into the OECD QSAR Toolbox.
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